BJDX
Bluejay Diagnostics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.70
−6.46%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.74
From 52W high−93.28%
Volume70417.00
Market cap$3.11M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.74
From 52W high
−93.28%
Volume
70417.00
Market cap
$3.11M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.9x
P/E (TTM)
—
RSI (14)
34.4
MomentumView details →
1D Return
−6.46%
YTD Return
−73.41%
SummaryUpdated Jun 1, 2026
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) is a medical device company founded in 2015 and headquartered in Acton, Massachusetts. The company went public in November 2021 and focuses on developing point-of-care diagnostic solutions for healthcare providers. Bluejay operates in the early-stage medical diagnostics sector, developing innovative testing platforms designed to improve patient care through rapid, accurate diagnostic capabilities at the point of care.
Similar companies
Latest newsMore news →
Bluejay Diagnostics completed establishment of a manufacturing site for Symphony cartridges, meeting a contractual milestone under its amended license agreement with Toray Industries.7d agoBluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study, covering 777 evaluable patients, as it advances the Symphony IL-6 Test toward regulatory submission.14d agoBluejay Diagnostics and Lovell Government Services announced a partnership to expand access to U.S. federal healthcare markets, establishing a federal distribution and co-marketing framework across VA, DoD, Military Health Systems and other government healthcare channels.42d ago